Amgen updates Vectibix safety information

Amgen has announced an update to the safety information on its metastatic colorectal cancer treatment Vectibix (Panitumumab).

In a statement, the organisation announced that the Food and Drug Administration has approved alterations to the data for the therapy after a meeting of the Oncologics Drugs Advisory Committee.

During the session, the clinical applications of the KRAS gene as a predictive biomarker in people with metastatic colorectal cancer who are treated with the anti-epidermal growth factor receptor (anti-EGFr) were discussed.

Commenting, Dr Sean Harper, chief medical officer and head of global development at Amgen, said that the firm is “pleased” with the FDA’s decision.

“With this label update, physicians can now eliminate anti-EGFr antibodies as a treatment option for patients with mutated KRAS tumours and redirect those patients to alternative therapies,” he added.

Earlier this month, Amgen announced that it has appointed Rebecca Henderson, a specialist in technology strategy, to its board.